SecBot SecBot

AZTR

Azitra, Inc.
NYSE· Pharmaceutical Preparations· Inc. DE· CIK 0001701478 Biotech & Drug Discovery
—
Market cap
$4.3M
Nano cap
Median target
🔒 Subscribers only
Short interest
240.8K
≈0.4% of shares · −65.7%
Days to cover
1.0
at average volume
Insider net
$0.00
1 buyer · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
9
analyzed by SecBot
SecBot read MIXED 5 reports · 90 days
Balance 1 bearish · 1 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/5
Strongest NEUTRAL Azitra, Inc. filed a certificate of amendment to effect a 1-for-10 reverse stock split, effective October…
All reports →

Price

Daily candles with volume.

Signal stack

Where each data set points today.

  • InsidersMIXED

    No open-market sales.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 1 trimmed or exited.

  • Short sellersCOVERING

    Short interest −65.7% to 240.8K shares. 1.0 days to cover, ≈0.4% of shares.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
GEODE CAPITAL MANAGEMENT, LLCNEAR_EXIT95,409$16.0K
UBS Group AGADD50,481$8.5K
CITIGROUP INCDOUBLED6,149$1.0K
GEODE CAPITAL MANAGEMENT, LLCDOUBLED469,878$110.0K
UBS Group AGDOUBLED30,205$7.1K
GEODE CAPITAL MANAGEMENT, LLCDOUBLED77,612$20.6K
BANK OF AMERICA CORP /DE/ADD72$19.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Sep 2025

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Sep 24, 2025Maxim Group
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 1 insider
$0
sold · 0 insiders
DateInsiderTypeValue
Jun 16, 2026
Salva Francisco D.
President and CEO
CONVERT4,064,050 sh
Jun 16, 2026
Salva Francisco D.
President and CEO
CONVERT500 sh
Apr 20, 2026
Salva Francisco D.
President and CEO
AWARD220,879 sh
Apr 20, 2026
Staskey Norm
Chief Financial Officer
AWARD35,524 sh
Apr 20, 2026
Whitfill Travis
Chief Operating Officer
AWARD64,300 sh
Mar 18, 2026
Salva Francisco D.
President and CEO
BUY500 sh
Mar 18, 2026
Salva Francisco D.
President and CEO
BUY4,064,050 sh
Mar 18, 2026
Salva Francisco D.
President and CEO
BUY4,064,050 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Sep 30, 2026
240,809
shares short
-65.7%
vs prior settlement
1.0
days to cover
≈0.4%
of shares outstanding
Trading halts
Oct 13, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 Trading halt
🔒 Fresh data, subscribers only
Oct 26, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 22, 2026 SEC
Azitra, Inc. filed a certificate of amendment to effect a 1-for-10 reverse stock split, effective October 26, 2026…
8-K — Impact 3/10
Oct 1, 2026 SEC
Azitra announced that its Phase 1/2 trial of ATR-04 for EGFR inhibitor-associated skin rash has cleared the safety…
8-K — Impact 4/10
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — NEAR_EXIT
95,409 shares ($16.0K)
Jun 30, 2026 Inst.
UBS Group AG — ADD
50,481 shares ($8.5K)
Jun 16, 2026 Insider
Salva Francisco D. acquired 4,064,050 shares
President and CEO
Jun 16, 2026 Insider
Salva Francisco D. disposed of 500 shares
President and CEO
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 26, 2026
Trading halt
🔒 Fresh data, subscribers only
Oct 16, 2026
Press release
Azitra, Inc. Announces Reverse Stock Split
Common Stock Will Begin Trading on a Split-Adjusted Basis on October 26, 2026 BRANFORD, Conn., Oct. 16, 2026 /PRNewswire/ -- Azitra, Inc. (NYSE…
Oct 13, 2026
Trading halt
Trading Halt: AZTR — H11 (Regulatory Concern)
Azitra Inc. | Market: AMEX | Code: H11 — Regulatory Concern
Aug 31, 2026
Short interest
Short Interest: AZTR up 6463% to 1.4M shares
Settlement 2026-08-31 | Days to cover: 1.00 | ≈2.26% of shares outstanding (est.)
Aug 21, 2026
Press release
Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards
BRANFORD, Conn., Aug. 21, 2026 /PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical…

SecBot reports

9 filings · 1 bullish · 3 bearish · 1 mixed · 4 neutral
All AZTR filing & press-release reports (9)